ライフサイエンスコーパス: de-escalation

1 microbial stewardship enhanced antimicrobial de-escalation.

2 resistant Gram-negative bacteria followed by de-escalation.

3 h cohorts at the starting dose required dose de-escalation.

4 eltamivir in infants aged <2 years in an age-de-escalation, adaptive design with a targeted systemic

5 Antimicrobial de-escalation (ADE) is a strategy to reduce the spectrum

6 ty of axillary management, and any policy of de-escalation and avoidance of morbidity must not compro

7 s the proportion of patients who lost MMR on de-escalation and regained MMR on TKI resumption.

8 ning patients who are candidates for therapy de-escalation), and not in Group 3 or SHH.

9 mmon interventions for self harm were verbal de-escalation, and manual restraint.

10 re has been a shift to a procedural conflict de-escalation approach to addressing clinical questions

11 Studies of more ambitious de-escalation are warranted.

12 We aimed to examine the effects of treatment de-escalation as a prelude to complete cessation, not on

13 rt-course treatment regimens and the use of 'de-escalation' as a strategy for antibiotic prescribing.

14 All 5 patients who underwent dose de-escalation, but neither of the control patients, expe

15 500 mg twice daily in a standard 3 + 3 dose de-escalation design.

16 terature to identify studies reporting after de-escalation (drug cessation or dose reduction) of anti

17 we analyzed findings from 69 studies (18 on de-escalation [drug cessation or dose reduction] of immu

18 There were two dose de-escalations due to neurotoxicity on this or other stu

19 It also has the potential to enable early de-escalation from broad-spectrum empirical antimicrobia

20 omodulator monotherapy, 8 on immunomodulator de-escalation from combination therapy, and 43 on de-esc

21 had a dose-limiting toxic effect in the dose de-escalation group receiving FOLFIRINOX plus PF-0413630

22 on-phase group (n=33) with those in the dose de-escalation group that received PF-04136309 at the rec

23 This trend for de-escalation has accompanied a shift in understanding o

24 Radiotherapy de-escalation has the potential to improve the therapeut

25 ysis the resulting theoretical definition of de-escalation in healthcare is "a collective term for a

26 olecular testing had the potential to enable de-escalation in number and/or spectrum of antimicrobial

27 late production; a trend toward evolutionary de-escalation in the numbers and diversity of glucosinol

28 py, we classified patients into four groups: de-escalation (interruption of an antimicrobial agent or

29 y purport to use, the antecedents that their de-escalation intervention is targeting, its key attribu

30 INTERPRETATION: TKI de-escalation is safe for most patients with excellent r

31 g a robust evidence-base for the efficacy of de-escalation is striking and must, at least in part, be

32 De-escalation is the recommended first-line response to

33 nsivists and infectious disease specialists, de-escalation may actually be possible in <50% of cases.

34 scalation than the control group (34%), with de-escalation occurring sooner in the BCID group (48 h;

35 most commonly reported environment in which de-escalation occurs, and nursing the disciplinary group

36 calation from combination therapy, and 43 on de-escalation of anti-TNF agents, including 3 during pre

37 e VAP so that appropriate discontinuation or de-escalation of antimicrobial therapy can be initiated

38 matic review and meta-analysis of studies of de-escalation of BMAs, and two randomized trials of BMAs

39 rminant of poor outcomes in this population, de-escalation of chemotherapy intensity might be feasibl

40 s change in antimicrobial prescriptions (ie, de-escalation of empirical antimicrobial therapy or comm

41 De-escalation of empirical vancomycin to definitive beta

42 mucosal and pharyngeal-related DLT required de-escalation of gemcitabine dose in successive patient

43 However, guidance regarding de-escalation of medical therapy is lacking.

44 -limiting myelosuppression persisted despite de-escalation of TOPO to 0.3 mg/m(2)/d and use of G-CSF.

45 To clarify the concept of de-escalation of violence and aggression as described wi

46 of the 18 patients and was managed with dose de-escalation or discontinuation per standard of care.

47 isease, as well as the possible strategy for de-escalation or discontinuation therapy.

48 from Gram stain to appropriate antimicrobial de-escalation or escalation was shortest in the rmPCR/AS

49 econdary outcomes were time to antimicrobial de-escalation or escalation, length of stay (LOS), morta

50 een studied, nor has the effect of treatment de-escalation rather than outright cessation.

51 calation was shortest in the rmPCR/AS group (de-escalation: rmPCR/AS 21 hours, control 34 hours, rmPC

52 igned by using a traditional dose-escalation/de-escalation rule based on observed toxicities in the c

53 s are exploring the feasibility of treatment de-escalation strategies in patients with a negative int

54 A dose de-escalation strategy identified recommended pralatrexa

55 Phase 1b was an open-label, dose de-escalation study to identify a safe dose of rilotumum

56 under suboptimal conditions, an antigen dose de-escalation study was performed in the presence of eit

57 olled in a masked, multicenter, phase 1 dose de-escalation study.

58 matched unrelated marrow and PBMCs in a dose de-escalation study.

59 aff response and environmental influences on de-escalation success and failure.

60 aff, patient and environmental influences on de-escalation success or failure.

61 De-escalation techniques are recommended to manage viole

62 To obtain staff descriptions of de-escalation techniques currently used in mental health

63 s to the implementation and effectiveness of de-escalation techniques in practice are not well unders

64 ntly conceptualised by staff as a feature of de-escalation techniques, yet, there was evidence of a l

65 se of restrictive practices through enhanced de-escalation techniques.

66 2%) groups had higher rates of antimicrobial de-escalation than the control group (34%), with de-esca

67 ausea) improved during the first 3 months of de-escalation, though not thereafter.

68 Dose escalation to 200 mg/m(2) and de-escalation to 110 mg/m(2) were allowed based on adver

69 he starting dose of 12 mg/m(2)/d resulted in de-escalation to 8 mg/m(2)/d and subsequent re-escalatio

70 was myelosuppressive, requiring several dose de-escalations to 2 mg/m(2), the dose suggested for phas

71 cardiac involvement were enrolled in a dose de-escalation trial.

72 Many radiation and chemotherapy de-escalation trials are underway.

73 ulated radiation therapy, immunotherapy, and de-escalation trials, might allow for improved treatment

74 De-escalation was applied in 93 episodes (43%), escalati

75 Due to toxicity, a dose de-escalation was made to EOC + P DL-1 (epirubicin 50 mg

76 De-escalation was possible for patients receiving weekly

77 Proposed theories or models of de-escalation were assessed against quality criteria.

78 Five theories of de-escalation were proposed; while each was adequate in

79 Information about the specific attributes of de-escalation were subject to thematic analysis.

80 ssessment of antimicrobial therapy daily for de-escalation, when appropriate (1B); infection source c